SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Launched by BIAL - PORTELA C S.A. ·
Trial Information
Current as of September 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called SL-START, is studying a treatment for Parkinson’s disease using a medicine called sublingual apomorphine (SL-APO), which is placed under the tongue to help manage symptoms when they suddenly get worse. The study aims to understand how patients and doctors adjust the dose of this medicine in real-life settings, and how these adjustments affect how satisfied patients are, how long they stay on the treatment, and the balance between how well the medicine works and any side effects.
The trial is looking for adults aged 65 to 74 with Parkinson’s disease, regardless of gender. While the study is not yet recruiting, participants can expect to work with their healthcare providers to find the right dose of SL-APO for them, based on their individual needs. This research could help improve how doctors prescribe this treatment in the future, making it easier and safer for patients to get the relief they need.
Gender
ALL
Eligibility criteria
About Bial Portela C S.A.
Bial - Portela C S.A. is a prominent pharmaceutical company based in Portugal, renowned for its commitment to research and development in the fields of neurology, psychiatry, and cardiovascular health. Established in 1924, Bial focuses on innovative solutions that address unmet medical needs while ensuring high standards of quality and efficacy. The company actively engages in clinical trials to advance its portfolio of proprietary products and contribute to global health improvements. With a strong emphasis on collaboration and scientific excellence, Bial strives to enhance patient outcomes through its dedication to cutting-edge medical research and development initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jan Kassubek, Prof Dr med
Principal Investigator
Praxis für Neurologie und Geriatrie (Ulm)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported